Literature DB >> 10146936

Health-related quality of life in pharmaceutical evaluation: forging progress and avoiding pitfalls.

D L Patrick.   

Abstract

Mesh:

Year:  1992        PMID: 10146936     DOI: 10.2165/00019053-199201020-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Forces motivating the use of health status assessment measures in clinical settings and related clinical research.

Authors:  S O Thier
Journal:  Med Care       Date:  1992-05       Impact factor: 2.983

3.  Power estimation for rank tests using censored data: conditional and unconditional.

Authors:  A B Cantor
Journal:  Control Clin Trials       Date:  1991-08

4.  Quality of life evaluation of antihypertensive drugs.

Authors:  C J Bulpitt; A E Fletcher
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 5.  Quality of life instruments in the evaluation of new drugs.

Authors:  R Jaeschke; G H Guyatt; D Cook
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

  5 in total
  4 in total

Review 1.  Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Authors:  R Whittington; L B Barradell; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

2.  Health-related quality of life in patients with insomnia treated with zopiclone.

Authors:  D Leger; M A Quera-Salva; P Philip
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 3.  Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.

Authors:  J C Gillis; K L Goa
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 4.  Quality-of-life instruments for severe chronic mental illness. Implications for pharmacotherapy.

Authors:  M Becker
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.